For samples of ER+ breast cancer patients receiving post-operative tamoxifen therapy, we firstly used the drug-free prognostic signature to recognize patients who would have been at low risk of recurrence if they had accepted surgery only, and then used the remained high-risk samples to develop a therapy benefit predictive signature for identifying patients who could benefit from tamoxifen therapy (Figure 2). This evidence concerns the gene ESR1 and breast cancer.